DBV Technologies S.A.DBVTEarnings & Financial Report
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Revenue
$2.2M
Gross Profit
N/A
Operating Profit
$-21.2M
Net Profit
$-20.6M
Gross Margin
N/A
Operating Margin
-964.7%
Net Margin
-937.1%
YoY Growth
-13.8%
EPS
$-0.22
DBV Technologies S.A. Q1 FY2023 Financial Summary
DBV Technologies S.A. reported revenue of $2.2M (down 13.8% YoY) for Q1 FY2023, with a net profit of $-20.6M (down 23.1% YoY) (-937.1% margin).
Key Financial Metrics
| Total Revenue | $2.2M |
|---|---|
| Net Profit | $-20.6M |
| Gross Margin | N/A |
| Operating Margin | -964.7% |
| Report Period | Q1 FY2023 |
DBV Technologies S.A. Annual Revenue by Year
DBV Technologies S.A. annual revenue history includes year-by-year totals (for example, 2023 revenue was $15.7M).
| Year | Annual Revenue |
|---|---|
| 2023 | $15.7M |
| 2022 | $4.8M |
DBV Technologies S.A. Quarterly Revenue & Net Profit History
DBV Technologies S.A. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $2.8M | +158.8% | $-33.2M | -1195.5% |
| Q2 FY2025 | $1.5M | +26.2% | $-41.9M | -2858.4% |
| Q2 FY2024 | $1.2M | -49.3% | $-33.1M | -2852.4% |
| Q1 FY2024 | $1.4M | -35.9% | $-27.3M | -1943.5% |
| Q4 FY2023 | $8.9M | +780.0% | $134.3M | 1512.8% |
| Q3 FY2023 | $2.4M | +14.4% | $-16.7M | -705.6% |
| Q2 FY2023 | $2.3M | +49.6% | $-24.2M | -1059.6% |
| Q1 FY2023 | $2.2M | -13.8% | $-20.6M | -937.1% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.3M | $2.4M | $8.9M | $1.4M | $1.2M | $1.5M | $2.8M |
| YoY Growth | -13.8% | 49.6% | 14.4% | 780.0% | -35.9% | -49.3% | 26.2% | 158.8% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $232.9M | $217.5M | $189.8M | $183.0M | $145.9M | $114.2M | $143.4M | $110.5M |
| Liabilities | $53.8M | $53.3M | $45.8M | $42.8M | $34.2M | $35.1M | $57.2M | $57.6M |
| Equity | $179.1M | $164.2M | $144.0M | $140.2M | $111.7M | $79.1M | $86.2M | $52.9M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.8M | $-25.6M | $-19.6M | $-13.7M | $-34.7M | $-35.1M | $-33.9M | $-32.4M |